Interference 102,760 a method for treatment of sleep apnea comprising administration of a therapeutically effective amount of buspirone to a patient in need of such treatment . . . . The date when such contribution was made was prior to April, 1986. . . .” (SRR, WIA, RI 2, p. 258). E. “Dement and . . . Rosekind conceived of at least a specific dosage of buspirone to be given to patients having sleep apnea at bedtime, i.e., 20 milligrams of buspirone. The date of this conception was prior to August 9, 1989. . . .” (SRR, WIA, RI 2, p. 259). F. “For all claims in which . . . Rosekind is identified as an inventor in response to Interrogatory No. 1 [(RI 1)], his contribution to the conception of the invention was his concept, along with Dr. Dement of at least a specific dosage of buspirone to be given to patients having sleep apnea at bedtime, i.e., 20 milligrams of buspirone. The date of this conception was prior to August 9, 1989. . . .” (SRR, WIA, RI 3, p. 260). G. “As to . . . claims 1, 2, 6, 7 and 13 of application Serial No. 07/695,325, the contribution of . . . Schwimmer to 12Page: Previous 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 NextLast modified: November 3, 2007